Barry Singer from Missouri Baptist Medical Center: Looking at Long Term Results of Fingolimod

In six years since fingolimod was approved for the treatment of relapsing remitting multiple sclerosis a considerable amount of data has been collected about the oral medication.

In 6 years since fingolimod was approved for the treatment of relapsing remitting multiple sclerosis a considerable amount of data has been collected about the oral medication.

Barry A. Singer, MD, from Missouri Baptist Medical Center discussed the results of the latest research on the medication during the annual ECTRIMS conference in London. Singer said the results in real world practice have proven to be similar to what was seen during clinical trials. This includes both efficacy and safety results. Singer also discussed why a small number of patients on the medication have developed progressive multifocal leukoencephalopathy and what has been learned about that condition in recent years as well.